Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of AFMD
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Affimed N.V. stock price ended at $5.33 on Wednesday, after gaining 0.188%.
(Updated on Mar 27, 2024)

Sell candidate since Mar 21, 2024 Gain 5.75% PDF

The Affimed N.V. stock price gained 0.188% on the last trading day (Wednesday, 27th Mar 2024), rising from $5.32 to $5.33. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 6.04% from a day low at $5.30 to a day high of $5.62. The price has risen in 6 of the last 10 days and is up by 11.27% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 42 thousand more shares were traded than the day before. In total, 99 thousand shares were bought and sold for approximately $529.96 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -13.18% during the next 3 months and, with a 90% probability hold a price between $3.69 and $5.75 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

AFMD Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, March 14, 2024, and so far it has risen 21.14%. Further rise is indicated until a new top pivot has been found. Affimed N.V. has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Affimed N.V. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $5.53. On a fall, the stock will find some support from the short-term average at $5.18. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Affimed N.V. stock

Affimed N.V. finds support from accumulated volume at $5.29 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.320 between high and low, or 6.04%. For the last week, the stock has had daily average volatility of 7.28%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (AFMD) For The Upcoming Trading Day Of Thursday 28th

For the upcoming trading day on Thursday, 28th we expect Affimed N.V. to open at $5.42, and during the day (based on 14 day Average True Range), to move between $4.79 and $5.87, which gives a possible trading interval of +/-$0.545 (+/-10.22%) up or down from last closing price. If Affimed N.V. takes out the full calculated possible swing range there will be an estimated 20.45% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $5.29 (0.75%) than the resistance at $5.70 (6.94%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Affimed N.V. stock A Buy?

Affimed N.V. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.760 Sell Candidate Unchanged

Predicted Opening Price for Affimed N.V. of Thursday, March 28, 2024

Fair opening price March 28, 2024 Current price
$5.42 ( 1.63%) $5.33

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for AFMD

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.74 7.63 %
R2 5.61 5.34 %
R1 5.54 3.92 %
Current price: 5.33
Support S1 5.29 -0.667 %
S2 5.22 -2.08 %
S3 5.10 -4.38 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 6.61 24.05 %
R2 6.25 17.26 %
R1 5.70 6.94 %
Current price 5.33
Support S1 5.29 -0.750%
S2 4.79 -10.13%
S3 4.40 -17.45%

FAQ

What is the symbol for Affimed N.V. Stock and on which exchange is it traded?
The symbol for Affimed N.V. is AFMD and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Affimed N.V. Stock?
Affimed N.V. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy Affimed N.V. Stock?
Affimed N.V. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Affimed N.V. Stock.

What's the current price of Affimed N.V. Stock?
As of the end of day on the 2024-03-27, the price of an Affimed N.V. (AFMD) share was $5.33.

What is the 52-week high and low for Affimed N.V. Stock?
The 52-week high for Affimed N.V. Stock is $11.10 and the 52-week low is $2.24.

What is the market capitalization of Affimed N.V. Stock?
As of the 2024-03-27, the market capitalization of Affimed N.V. is 79.598M.

When is the next earnings date for Affimed N.V.?
The upcoming earnings date for Affimed N.V. is Mar 28, 2024.
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT